发明名称 |
Use of calcitonin in osteoarthritis |
摘要 |
The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans. |
申请公布号 |
US8765675(B2) |
申请公布日期 |
2014.07.01 |
申请号 |
US201012819583 |
申请日期 |
2010.06.21 |
申请人 |
Novartis AG |
发明人 |
Azria Moise;Christiansen Claus;Bateman Simon David;Li Shoufeng |
分类号 |
A61K38/23;A61P19/00;A61P19/02;A61P19/08;A61P19/10;C07K14/585 |
主分类号 |
A61K38/23 |
代理机构 |
Dilworth & Barrese, LLP |
代理人 |
Pokalsky Ann R.;Dilworth & Barrese, LLP |
主权项 |
1. A method of reducing cartilage degeneration and/or bone resorption in an osteoarthritis patient or in a post-menopausal woman, said method comprising orally administering to said patient or to said post-menopausal woman, a pharmaceutical composition comprising salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzyol]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and disodium salts thereof, wherein the amount of said salmon calcitonin in said pharmaceutical composition is between 0.4 and 1.2 mg. |
地址 |
Basel CH |